Opinion|Videos|January 16, 2025
Episode 2 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Author(s)Wayne Kuang, MD, Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Advertisement
Advertisement
Trending on Urology Times
1
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5